| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8623798 | Seminars in Arthritis and Rheumatism | 2018 | 24 Pages |
Abstract
No changes in drug trough levels or objective parameters were observed after the systematic switch to biosimilar infliximab in a real clinical practice setting. Only changes in patient-reported outcomes were observed, suggesting attribution effects rather than pharmacological differences.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Jérôme PhD, Anna PhD, Vered MD, Adrien PhD, Axelle MD, Loriane PhD, Caroline MD, Muriel PhD, Pascal MD, Pierre Antoine MD, Florence PhD, Ornella PhD, François PhD, Claire PhD, Claire Le PhD, Stanislas PhD, André PhD, Christian PhD, Maxime PhD,